Physician profile
Rohit Malik
NPI 1144285164
$7,689.29
in general payments reported to CMS, 2019-2025
33 companies · $1,197 in 2025
The $1,197 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,981 · 2020: $47.65 · 2021: $544 · 2022: $606 · 2023: $408 · 2024: $906 · 2025: $1,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,510.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,495.35 | 2019 | |
| Abbvie INC. | $1,077.93 | 2019-2025 | |
| Janssen Biotech, INC. | $884.17 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $556.83 | 2019-2025 | |
| Lilly USA, LLC | $172.24 | 2024-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $171.90 | 2021-2025 | Entyvio |
| Celltrion USA INC. | $146.19 | 2025 | Vegzelma |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $134.12 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Celgene Corporation | $123.75 | 2021-2024 | Zeposia |
| Genzyme Corporation | $107.83 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $97.73 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $91.05 | 2024-2025 | Rezdiffra, Resmetirom |
| Ironwood Pharmaceuticals, INC | $87.24 | 2019-2024 | |
| Ardelyx, INC. | $56.41 | 2024-2025 | Ibsrela |
| Amgen INC. | $52.41 | 2022-2025 | Uplizna |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $50.87 | 2024 | Sucraid |
| Romark Laboratories, Lc | $44.92 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $44.86 | 2023 | Dupixent |
| Aimmune Therapeutics, INC. | $36.84 | 2025 | Zenpep |
| Gilead Sciences, INC. | $32.46 | 2019 | |
| Intercept Pharmaceuticals, INC. | $30.91 | 2023 | Ocaliva |
| Organon LLC | $24.32 | 2023 | Renflexis |
| Ipsen Biopharmaceuticals, INC | $21.21 | 2024 | Iqirvo |
| Evoke Pharma, INC. | $19.87 | 2024 | |
| Merck Sharp & Dohme LLC | $19.38 | 2019 | |
| Axonics, INC. | $16.56 | 2024 | Axonics |
| Intra-Sana Laboratories | $15.65 | 2022 | |
| Ferring Pharmaceuticals INC. | $13.84 | 2023 | Rebyota |
| Mauna Kea Technologies, INC. | $13.44 | 2019 | |
| Braintree Laboratories, INC. | $13.26 | 2022 | |
| Nestle Healthcare Nutrition INC. | $12.37 | 2021 | |
| Shionogi INC | $12.28 | 2019 | |
| Boston Scientific Corporation | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.